Oyster Point Pharma has enrolled the first patient in a phase 3 trial of OC-01, a nasal spray treatment candidate for the signs and symptoms of dry eye disease, according to a press release.
The multicenter, randomized, double-masked, placebo-controlled ONSET-2 clinical trial will evaluate the safety and efficacy of OC-01 in two doses, 0.6 mg/mL and 1.2 mg/mL, vs. placebo in 750 subjects at 20 U.S. centers.
“We believe OC-01 has the potential to change the way that eye care practitioners treat patients with dry eye disease due to the rapid onset of action in increasing natural tear filmThe outer layer is an oil- or lipid-based layer, which helps reduce evaporation of the natural tears. …
Read More: Oyster Point begins dry eye nasal spray phase 3 trial